[1] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 实用肝脏病杂志,2023,26(2):305-318.
[2] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet,2020,396(10258):1204-1222.
[3] Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021,398(10308):1359-1376.
[4] 中华医学会消化病学分会消化微创介入协作组. 经颈静脉肝内门体静脉分流术治疗门静脉高压专家共识. 中华消化杂志,2023,43(5):289-307.
[5] Liu J, Meng J, Zhou C, et al. A new choice of stent for transjugular intrahepatic portosystemic shunt creation: Viabahn ePTFE covered stent/bare metal stent combination. J Interv Med,2020,4(1):32-38.
[6] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021,74(2):1014-1048.
[7] Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut,2021,70(1):9-29.
[8] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022,76(4):959-974.
[9] Guerrero A, Campo LD, Piscaglia F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis. J Hepatol,2023,79(1):69-78.
[10] 赵平,黎涛,谢吉良,等. 早期抗凝干预用于经颈静脉肝内门体静脉支架分流术联合PSE治疗肝硬化患者价值探讨. 实用肝脏病杂志,2020,23(1):82-85.
[11] 夏翊夫,宋丽君,王广川,等. 经颈静脉肝内门体静脉分流术后支架堵塞的影响因素及抗凝治疗必要性分析. 中华肝脏病杂志,2022,30(7):728-734.
[12] Jiao P, Chen XY, Zheng HY, et al. Anticoagulation after transjugular intrahepatic portosystemic shunt for portal hypertension: A systematic review and meta analysis. Medicine (Baltimore),2022,101(26):e29742.
[13] Wang YM, Li YH, Wu HM, et al. Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt: Risk factors, warfarin efficacy, and clinical outcomes. Clin Appl Thromb Hemost,2021,24(3):462-470.
[14] Tang Y, Zheng S, Yang J, et al. Use of concomitant variceal embolization and prophylactic antiplatelet/anticoagulative in transjugular intrahepatic portosystemic shunting: A retrospective study of 182 cirrhotic portal hypertension patients. Medicine (Baltimore),2017,96(49):e8678.
[15] Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol,2021,75(2):442-453.
[16] Yeoh SW, Kok HK. Transjugular intrahepatic portosystemic shunts in portal vein thrombosis: A review. J Dig Dis. 2021,22(9):506-519.
[17] Wang Z, Jiang MS, Zhang HL,et al. Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial. Radiology,2016,279(3):943-951.
[18] Lisman T, Hernandez-Gea V, Magnusson M, et al. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost, 2021,19(4):1116-1122.
[19] O'Shea RS, Davitkov P, Ko CW, et al. AGA Clinical Practice Guideline on the management of coagulation disorders in patients with cirrhosis. Gastroenterology, 2021,161(5):1615-1627.
[20] Goessmann H, Schuffenhauer V, Kandulski A, et al. Retrospective evaluation of early thrombosis in transjugular intrahepatic portosystemic polytetrafluoroethylene-coated shunts under 2-day postinterventional heparinization. Sci Rep, 2022,12(1):10506.
[21] Khizroeva J, Makatsariya A, Vorobev A,et al. The hemostatic system in newborns and the risk of neonatal thrombosis. Int J Mol Sci, 2023,24(18):13864.
[22] Han JM, Koh Y, Kim SH,et al. Evaluation of low-molecular-weight heparin for treatment of portal vein thrombosis in liver cirrhosis patients. Medicina (Kaunas), 2023,59(2):292.
[23] Sauer P, Theilmann L, Herrmann S, et al. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial. Hepatology, 1996,24(6):1433-1436.
[24] Nassar A, Huber JP, Stallmann D, et al. Decreased platelet aggregation in patients with decompensated liver cirrhosis and TIPS implantation. Biomedicines,2023,11(7):2057.
[25] Siegerstetter V, Huber M, Ochs A, et al. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin
treatment. Hepatology, 1999,29(1):33-38.
[26] Seifert LL, Schindler P, Sturm L,et al. Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study. Hepatol Int, 2022,16(3):658-668.
[27] Park SW, Cha IH, Kim CH, et al. Improved patency of transjugular intrahepatic portosystemic shunt: the efficacy of cilostazol for the prevention of pseudointimal hyperplasia in swine TIPS models. Cardiovasc Intervent Radiol,2007,30(4):719-724.
[28] Koh JH, Liew ZH, Ng GK,et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis,2022,54(1):56-62.
[29] Lyu Y, Bai W, Li K,et al. Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: A prospective observational study. Am J Gastroenterol, 2021,116(7):1447-1464.
[30] 孔德元,更藏尖措,颜小明,等. 利伐沙班预防TIPS术后血栓的安全性和有效性. 肝胆胰外科杂志,2023,35(8):464-468.
[31] Mort JF, Davis JPE, Mahoro G,et al. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis. Clin Gastroenterol Hepatol, 2021,19(7):1436-1442.
[32] Tang K, Weinberg EM. Direct oral anticoagulants in the treatment of portal vein thrombosis in patients with portal hypertension. Clin Liver Dis (Hoboken), 2023,22(2):37-41.
[33] Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic portosystemic stent shunt in the management of portal hypertension. Gut, 2020,69(7):1173-1192.
[34] Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol, 2021,56(7):593-619.
[35] Busk TM, Bendtsen F, Henriksen JH, et al. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis. Dig Liver Dis,2017,49(12):1353-1359.
[36] Caiano LM, Riva N, Carrier M,et al. Treatment of portal vein thrombosis: an updated narrative review. Minerva Med,2021,112(6):713-725.
[37] Desai NR, Cornutt D. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists. Hosp Pract (1995), 2019,47(3):113-122.
[38] Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int, 2021,15(3):531-567.
[39] Haque LY, Lim JK. Tailoring stepwise treatment for Budd-Chiari syndrome: insights from the Asian Pacific Association for the Study of the Liver (APASL) consensus guidance. Hepatobiliary Surg Nutr,2023,12(1):118-120.
[40] 王钲钰,雒博晗,吕勇,等. 肝硬化门静脉血栓患者经颈静脉肝内门体分流术后华法林抗凝治疗中出血事件发生情况及危险因素分析. 药物不良反应杂志,2018,20(4):259-265.
[41] Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci, 2009,30(7):375-386.
[42] 中华医学会放射学分会护理工作组. 门静脉高压患者经颈静脉肝内门体分流术护理管理专家共识. 介入放射学杂志,2022,31(2):117-124.
[43] 刘秀梅,郭倩倩,方圆等.经颈静脉肝内门体分流术后患者抗栓治疗的药学监护实践.中国临床药理学与治疗学,2023,28(5):556-560. |
